Siemens Healthineers sees Q4 revenue jump 19%

By staff writers

November 4, 2021 -- Siemens Healthineers saw revenue for the company's fiscal fourth quarter jump 19% after adjustment for currency changes. The increase was driven by 11% growth in the company's medical imaging business and a 22% spike in its diagnostics segment.

For the quarter (end-September 30), Siemens Healthineers posted sales of 5.164 billion euros ($5.966 billion), compared with 3.876 billion ($4.478 billion) euros in the fourth quarter of fiscal 2020. The increase was 33.2% on an actual basis, and up 14.4% after adjusting for currency effects and changes in the company's portfolio, such as its acquisition of radiation therapy company Varian.

The company's net income for the period was 466 million euros ($538 million), up 8% compared with 432 million euros ($499 million) in the same period the year before.

In Siemens' Imaging business, the segment recorded revenues of 2.757 billion euros ($3.185 billion), up 11.6% after currency adjustment compared with 2.477 billion euros ($2.861 billion) in the same period the year before, when the company's revenues were "challenged" by the COVID-19 pandemic. Double-digit growth was recorded in CT, ultrasound, and molecular imaging.

In its Diagnostics business, revenues were 1.278 billion ($1.476 billion), up 22.3% after currency adjustment compared with sales of 1.038 billion ($1.199 billion) in the same period the year before. Sales of rapid antigen tests generated 160 million euros ($185 million) in revenue in the quarter.

The company's Advanced Therapies business produced 499 million euros ($576 million), while the Varian business contributed 709 million ($819 million) in sales.

Siemens partners with A1 on COVID variant tracking
Siemens Healthineers announced that it is collaborating with A1 Life Sciences to support global efforts to track variants of SARS-CoV-2.
Siemens gets FDA nod for ELF test for liver fibrosis
Siemens Healthineers has been granted marketing authorization from the U.S Food and Drug Administration (FDA) for its Enhanced Liver Fibrosis (ELF) test,...
Siemens posts strong revenue, earnings growth in Q1
Benefiting from ongoing demand for products related to the COVID-19 pandemic and recovery in its core businesses, Siemens Healthineers exceeded market...
Siemens' SARS-CoV-2 test measures neutralizing antibodies
Siemens Healthineers has announced that its SARS-CoV-2 immunoglobin G antibody test is able to measure neutralizing antibodies for the virus.
Siemens Healthineers posts dip in Q4 revenues
Siemens Healthineers posted a 2% decline in revenues for the company's fourth quarter of fiscal 2020. Net income also slipped for the period, but the...

Copyright © 2021

Last Updated bc 11/5/2021 6:28:29 AM